Literature DB >> 21129907

Iliofemoral stenting for venous occlusive disease.

Jessica M Titus1, Mireille A Moise, James Bena, Sean P Lyden, Daniel G Clair.   

Abstract

BACKGROUND: Venous hypertension is a significant cause of patient morbidity and decreased quality of life. Common etiologies of venous hypertension include deep venous thrombosis (DVT) or congenital abnormalities resulting in chronic outflow obstruction. We have implemented an aggressive endovascular approach for the treatment of iliac venous occlusion with angioplasty and stenting. The purpose of this study was to determine the patency rates with this approach at a large tertiary care center. MATERIALS/
METHODS: All patients undergoing iliofemoral venous angioplasty and stenting over a 4-year period were identified from a vascular surgical registry. Charts were reviewed retrospectively for patient demographics, the extent of venous system involvement, the time course of the venous pathology, and any underlying cause. Technical aspects of the procedure including previous angioplasty or stenting attempts and presence of collaterals on completion venogram were then recorded. Patency upon follow-up was determined using primarily ultrasound scans; other imaging methods were used if patency was not clear using an ultrasound scan.
RESULTS: A total of 36 patients (40 limbs) were stented from January 2005 through December 2008. Of these patients, 27 were women (75%). Both lower extremities were involved in 4 patients. Thrombolysis was performed in 19 patients (52.8%). Thrombosis was considered acute (<30 days) in 13 patients (38%). The majority of patients who had a recognized underlying etiology were diagnosed with May-Thurner syndrome (15 patients; 42%). In 9 patients, an etiology was not determined (25%). The mean follow-up time period in the study population was 10.5 months. One stent in the study occluded acutely and required restenting. Primary patency rates at 6, 12, and 24 months were 88% (75.2-100), 78.3% (61.1-95.4), and 78.3% (61.1-95.4), respectively. Secondary patency rates for the same time frames were 100% (100.0, 100.0), 95% (85.4, 100.0), and 95% (85.4, 100.0). Better outcomes were seen in stenting for May-Thurner syndrome and idiopathic causes, whereas external compression and thrombophilia seemed to portend less favorable outcomes (P < .001). Symptomatic improvement was reported in 24 of 29 patients (83%) contacted by telephone follow-up.
CONCLUSION: Iliofemoral venous stenting provides a safe and effective option for the treatment of iliac venous occlusive disease. Acceptable patency rates can be expected through short-term follow-up, especially in the case of May-Thurner syndrome. Further experience with this approach and longer-term follow-up is necessary. Thrombophilia workup should be pursued aggressively in this population, and further studies should be undertaken to determine the optimal length of anticoagulation therapy after stent placement.
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129907     DOI: 10.1016/j.jvs.2010.09.011

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  20 in total

1.  Endovascular Treatment of Iliac Vein Compression (May-Thurner) Syndrome: Angioplasty and Stenting with or without Manual Aspiration Thrombectomy and Catheter-Directed Thrombolysis.

Authors:  Halil Bozkaya; Celal Cinar; Serkan Ertugay; Mehmet Korkmaz; Serkan Guneyli; Hakan Posacioglu; Mustafa Parıldar
Journal:  Ann Vasc Dis       Date:  2015-02-16

Review 2.  Minimally invasive treatments for venous compression syndromes.

Authors:  Paul C Hulsberg; Eric McLoney; Sasan Partovi; Jon C Davidson; Indravadan J Patel
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

3.  Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement.

Authors:  Marie-Tiphaine Falcoz; Nicolas Falvo; Serge Aho-Glélé; Emmanuel Demaistre; Christophe Galland; Sylvain Favelier; Pierre Pottecher; Olivier Chevallier; Bernard Bonnotte; Sylvain Audia; Maxime Samson; Béatrice Terriat; Marco Midulla; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2016-08

4.  Acute bilateral pulmonary embolism in a 21-year-old: is May-Thurner syndrome in our differential?

Authors:  Rajarshi Bhadra; Meyappan Somasundaram; Daniel V Iltchev; Keyvan Ravakhah
Journal:  BMJ Case Rep       Date:  2019-04-01

5.  Investigation of adverse events associated with an off-label use of arterial stents and CE-marked iliac vein stents in the iliac vein: insights into developing a better iliac vein stent.

Authors:  Takuya Shida; Mitsuo Umezu; Kiyotaka Iwasaki
Journal:  J Artif Organs       Date:  2018-02-06       Impact factor: 1.731

6.  Recurrent unilateral cellulitis: is it May-Thurner syndrome (MTS)?

Authors:  Kay Tai Choy; Sherab Bhutia
Journal:  BMJ Case Rep       Date:  2019-07-04

7.  Outcomes of venoplasty with stent placement for chronic thrombosis of the iliac and femoral veins: single-center experience.

Authors:  Andrew K Kurklinsky; Haraldur Bjarnason; Jeremy L Friese; Waldemar E Wysokinski; Robert D McBane; Andrew Misselt; Sigridur Margret Moller; Peter Gloviczki
Journal:  J Vasc Interv Radiol       Date:  2012-06-13       Impact factor: 3.464

8.  Treatment of May-Thurner's Syndrome and Associated Complications: A Multicenter Experience.

Authors:  Priscilla Sigua-Arce; Ramy Mando; Lisa Spencer; Alexandra Halalau
Journal:  Int J Gen Med       Date:  2021-08-20

9.  Atrial embolism caused by portal vein embolization: Treatment by percutaneous withdrawal and stenting.

Authors:  Ahmed Fouad Bouras; Stéphanie Truant; Jean-Paul Beregi; Geraldine Sergent; Olivier Delemazure; Guido Liddo; Gilles Lebuffe; Philippe Zerbib; François-René Pruvot; Emmanuel Boleslawski
Journal:  World J Hepatol       Date:  2012-12-27

10.  Timing of Endovascular Interventions for Iliac Vein Compression Syndrome With Thrombus.

Authors:  Wenxu Jin; Guanfeng Yu; Jingyong Huang; Kangkang Lu; Chongqing Huang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.